Skip to content
lifestyle.forkstofeet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Humacyte, Inc
Humacyte’s Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
June 15, 2026
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
June 10, 2026
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
June 10, 2026
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
June 10, 2026
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
June 10, 2026
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
May 26, 2026
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
April 27, 2026
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®
April 24, 2026
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
April 22, 2026
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
April 21, 2026
1
2
Next Page
→